jeudi 8 novembre 2018

Onco Actu du 8 novembre 2018


1.4 Biologie - Technos

WUSTL Software Offers Automated Option for Cancer Variant Review [Genome Web]

Machine-learning algorithm predicts how cells repair broken DNA [Broad Institute]

4.2 Dép., diag. & prono. - Génome

Cancer Exomes Alone May Provide Inaccurate Look at Tumor Somatic Subpopulations [Genome Web]

5.1 Traitements - Pré-clinique

How Melanoma Evades Targeted Therapies [Thomas Jefferson University]

New BRAF insight sheds light on strategy against drug-resistant melanoma [FierceBiotech]

5.10 Traitements - Essais

Cancer drug trial studies urged to report harms transparently [ecancer news]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Groundbreaking New Car T Cell Trial Opens For Patients With Breast Cancer That Has Spread To The Brain [City of Hope]

5.12.9 Immunothérapies - SITC

Radical optimism: considering the future of immunotherapy [SugarCone Biotech]

Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting [Merck]

SITC18: Merck highlights new LAG-3 and TIGIT data [FierceBiotech]

NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC) [nanoString]

5.3 Traitements - FDA, EMA, NICE...

Improving Availability of Medicines in the EU [ESMO]

5.3.4 Traitements - AMM (FDA, EMA,...)

Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma [FiercePharma]

FDA approves BMS' multiple myeloma combo after it doubles progression-free survival [Pharmafile]

6.1 Observation

Early birds have lower breast cancer risk? What you need to know [HealthNewsReview]

6.10.1 Politiques (USA)

With a new Congress, a window opens to finally bring down drug prices [STAT]

6.7.1 IA/bioinformatique

Could artificial intelligence make doctors obsolete? [BMJ]

Clinical Decision Support in the Era of Artificial Intelligence [JAMA]

6.8 Communication

Which media reaches cancer patients? Depends on their diagnosis: report [FiercePharma]